Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-2189 + HRS-6209 + HRS-1358
- Development stage
- Unknown
- Lead developer
- Shandong Suncadia Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HRS-2189 + HRS-6209 + HRS-1358 is a combination of three investigational small molecule drugs being evaluated for the treatment of advanced unresectable or metastatic breast cancer. HRS-2189, developed by Shandong Suncadia Medicine, is in phase II trials, though the specific target is not publicly identified[1][3][5]. HRS-6209, developed by Jiangsu Hengrui Pharmaceuticals, is a cyclin-dependent kinase 4 (CDK4) inhibitor[2]. HRS-1358 is included in ongoing clinical studies in combination but its mechanism, chemical class, and developer are not publicly disclosed. The drug combination is being assessed for safety, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, and preliminary efficacy in Phase I/II clinical trials in breast cancer patients[1][2]. No brand names besides code names have been reported.
- Other names
- HRS-2189HRS2189HRS 2189HRS-6209HRS6209HRS 6209HRS-1358HRS1358HRS 1358
02
Targets
ER (Estrogen receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)KAT6A (Lysine acetyltransferase 6A)
Beyond the preview
Go deeper on HRS-2189 + HRS-6209 + HRS-1358.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-2189 + HRS-6209 + HRS-1358.